Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

CPTx

Explore full profile

At CPTx, new treatment paradigms are developed to address unmet medical challenges, with an initial focus on infectious diseases

Planegg, GermanyFounded 2021Biotech & Life Sciences
Valuation $100–250M Last recorded · 2024
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for CPTx and the history behind them.

About CPTx

CPTx is a pioneering biotechnology company dedicated to developing innovative treatment paradigms for unmet medical challenges, with an initial focus on infectious diseases. Our mission is to revolutionize the way these conditions are treated, improving patient outcomes and addressing critical global health needs.

Read full description

At CPTx, we leverage cutting-edge science and technology to identify and advance novel therapeutic approaches. Our interdisciplinary team of scientists, researchers, and industry experts is committed to pushing the boundaries of medical innovation to create effective and accessible treatments for patients worldwide.

Our primary focus is on infectious diseases, which continue to pose significant threats to public health. By targeting these diseases, we aim to develop new therapies that can combat drug resistance, enhance treatment efficacy, and reduce the burden of infection. Our research and development efforts are guided by a deep understanding of disease mechanisms and a commitment to rigorous scientific inquiry.

CPTx's innovative approach includes the exploration of new molecular targets, the development of advanced drug delivery systems, and the application of state-of-the-art diagnostic tools. We collaborate with leading academic institutions, research organizations, and industry partners to accelerate the translation of our discoveries into clinical applications.

In addition to our focus on infectious diseases, CPTx is committed to addressing other unmet medical needs. Our platform technologies and scientific expertise enable us to explore a wide range of therapeutic areas, from rare diseases to chronic conditions. By pursuing a multi-faceted approach, we aim to create a diverse pipeline of innovative treatments that can transform patient care.

At CPTx, we are driven by a passion for improving lives and a dedication to scientific excellence. Our commitment to ethical and responsible research ensures that our solutions are developed with the well-being of patients and the broader community in mind.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2021
Headquarters
Planegg, Germany
Employees
49
Open positions
None listed
Dealroom signal
84.9/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Drug Development, DNA, Infections and Infectious Diseases, Genetics and genomics, Gene Therapy, Disease, Biotech and Pharma, DT and LS
Business model
Manufacturing
Client focus
b2b

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Sep 2024 $29M $116M Andrej Henkler · Bayern Kapital · Stefan Oschmann · BlueYard Capital ↗
SEED✓Equity / VC Feb 2024 — — BlueYard Capital —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

CPTx website traffic

Latest recorded traffic for CPTx is 2.6K monthly website visits, up 160% over the last three months. CPTx's team grew 14% over the past year.

Latest monthly visits2.6K 3-month web change+160% 1-year team growth+14%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • BlueYard Capital

Series A4 investors entered at this stage

  • SPRIN-D
  • Andrej Henkler
  • Bayern Kapital
  • Stefan Oschmann

Other known investors1 additional known investor

  • Leblon Capital
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇩🇪 Germany88.6%
🇺🇸 United States5.7%
🇨🇦 Canada2.9%
🇨🇭 Switzerland2.9%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about CPTx on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See CPTx’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.